Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes
- PMID: 28971838
- DOI: 10.1152/ajpgi.00216.2017
Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes
Abstract
Patients with type 2 diabetes (T2D) and patients with nonalcoholic fatty liver disease (NAFLD) frequently exhibit elevated plasma concentrations of glucagon (hyperglucagonemia). Hyperglucagonemia and α-cell hyperplasia may result from elevated levels of plasma amino acids when glucagon's action on hepatic amino acid metabolism is disrupted. We therefore measured plasma levels of glucagon and individual amino acids in patients with and without biopsy-verified NAFLD and with and without type T2D. Fasting levels of amino acids and glucagon in plasma were measured, using validated ELISAs and high-performance liquid chromatography, in obese, middle-aged individuals with I) normal glucose tolerance (NGT) and NAFLD, II) T2D and NAFLD, III) T2D without liver disease, and IV) NGT and no liver disease. Elevated levels of total amino acids were observed in participants with NAFLD and NGT compared with NGT controls (1,310 ± 235 µM vs. 937 ± 281 µM, P = 0.03) and in T2D and NAFLD compared with T2D without liver disease (1,354 ± 329 µM vs. 511 ± 235 µM, P < 0.0001). Particularly amino acids with known glucagonotropic effects (e.g., glutamine) were increased. Plasma levels of total amino acids correlated to plasma levels of glucagon also when adjusting for body mass index (BMI), glycated hemoglobin (HbA1c), and cholesterol levels (β = 0.013 ± 0.007, P = 0.024). Elevated plasma levels of total amino acids associate with hyperglucagonemia in NAFLD patients independently of glycemic control, BMI or cholesterol - supporting the potential importance of a "liver-α-cell axis" in which glucagon regulates hepatic amino acid metabolism. Fasting hyperglucagonemia as seen in T2D may therefore represent impaired hepatic glucagon action with increasing amino acids levels. NEW & NOTEWORTHY Hypersecretion of glucagon (hyperglucagonemia) has been suggested to be linked to type 2 diabetes. Here, we show that levels of amino acids correlate with levels of glucagon. Hyperglucagonemia may depend on hepatic steatosis rather than type 2 diabetes.
Keywords: amino acids; glucagon; hyperglucagonemia; nonalcoholic liver disease; type 2 diabetes.
Similar articles
-
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G558-G570. doi: 10.1152/ajpgi.00147.2024. Epub 2024 Aug 6. Am J Physiol Gastrointest Liver Physiol. 2024. PMID: 39104323
-
The Liver-α-Cell Axis and Type 2 Diabetes.Endocr Rev. 2019 Oct 1;40(5):1353-1366. doi: 10.1210/er.2018-00251. Endocr Rev. 2019. PMID: 30920583 Review.
-
Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects.Metab Syndr Relat Disord. 2018 Dec;16(10):530-536. doi: 10.1089/met.2018.0066. Epub 2018 Oct 16. Metab Syndr Relat Disord. 2018. PMID: 30325692
-
Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.Mol Metab. 2020 Dec;42:101080. doi: 10.1016/j.molmet.2020.101080. Epub 2020 Sep 13. Mol Metab. 2020. PMID: 32937194 Free PMC article.
-
The Liver-α-Cell Axis in Health and in Disease.Diabetes. 2022 Sep 1;71(9):1852-1861. doi: 10.2337/dbi22-0004. Diabetes. 2022. PMID: 35657688 Free PMC article. Review.
Cited by
-
Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease.Endocr Connect. 2023 Dec 8;13(1):e230161. doi: 10.1530/EC-23-0161. Print 2024 Jan 1. Endocr Connect. 2023. PMID: 37947763 Free PMC article.
-
Hepatic glucose metabolism in the steatotic liver.Nat Rev Gastroenterol Hepatol. 2024 May;21(5):319-334. doi: 10.1038/s41575-023-00888-8. Epub 2024 Feb 2. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38308003 Review.
-
Role of serum fasting glucagon in hypothyroidism-related nonalcoholic fatty liver disease.Nutr Metab (Lond). 2025 Mar 11;22(1):19. doi: 10.1186/s12986-025-00899-z. Nutr Metab (Lond). 2025. PMID: 40069760 Free PMC article.
-
Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet.Physiol Rep. 2025 Feb;13(4):e70235. doi: 10.14814/phy2.70235. Physiol Rep. 2025. PMID: 39985139 Free PMC article.
-
Upregulated TGF-β1 contributes to hyperglycaemia in type 2 diabetes by potentiating glucagon signalling.Diabetologia. 2023 Jun;66(6):1142-1155. doi: 10.1007/s00125-023-05889-5. Epub 2023 Mar 14. Diabetologia. 2023. PMID: 36917279
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical